Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% with semaglutide.[1] That gap is not small, and for patients in Shreveport asking which medication is the better choice, this study provides the clearest evidence yet
A three-year clinical study of semaglutide, sold under the brand names Ozempic and Wegovy, is underway in more than 1,800 people with early Alzheimer's disease
Before reviewing these reports, its important to understand what case reports can and cannot tell us
Lead plaintiffs' attorney Jonathan Orent told USA TODAY that the warning letter "gives me tremendous comfort both that we're right, but also that the government is actually now doing something about these problems." He compared the reporting failures to "the opioid days," noting that expert witnesses reviewing the case had "not seen anything quite that bad." Novo Nordisk responded that the letter "does not make any conclusions about the quality or safety of our medicines" and that the company plans to "address the requests in the warning letter expeditiously and holistically." What This Means for GLP-1 Litigation Strengthening Failure-to-Warn Claims The warning letter provides plaintiffs' attorneys with a critical piece of evidence: documentation that Novo Nordisk had institutional procedures that systematically prevented adverse events from reaching the FDA
They may recommend temporarily adjusting your dose
